Juarez JC - Search Results

1

Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.

Allan AL, Gladstone PL, Price ML, Hopkins SA, Juarez JC, Doñate F, Ternansky RJ, Shaw DE, Ganem B, Li Y, Wang W, Ealick S. Allan AL, et al. Among authors: juarez jc. J Med Chem. 2006 Dec 28;49(26):7807-15. doi: 10.1021/jm060428u. J Med Chem. 2006. PMID: 17181163

2

Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model.

Price ML, Guida WC, Jackson TE, Nydick JA, Gladstone PL, Juarez JC, Doñate F, Ternansky RJ. Price ML, et al. Among authors: juarez jc. Bioorg Med Chem Lett. 2003 Jan 6;13(1):107-10. doi: 10.1016/s0960-894x(02)00828-4. Bioorg Med Chem Lett. 2003. PMID: 12467627

3

Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1.

Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Doñate F. Juarez JC, et al. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. doi: 10.1158/1078-0432.CCR-06-0171. Clin Cancer Res. 2006. PMID: 16914587

4

Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells.

Guan X, Juarez JC, Qi X, Shipulina NV, Shaw DE, Morgan WT, McCrae KR, Mazar AP, Doñate F. Guan X, et al. Among authors: juarez jc. Thromb Haemost. 2004 Aug;92(2):403-12. doi: 10.1160/TH04-02-0073. Thromb Haemost. 2004. PMID: 15269838

The anti-angiogenic properties of the histidine-proline-rich (H/P) domain of HPRG have recently been described (Juarez JC, et al. Cancer Research 2002; 62: 5344-50). However, the binding site that mediates these properties is unknown. ...

The anti-angiogenic properties of the histidine-proline-rich (H/P) domain of HPRG have recently been described (Juarez JC, et …

5

Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.

Doñate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel-Tsur Z, Shaw DE, Morgan WT, Mazar AP. Doñate F, et al. Among authors: juarez jc. Cancer Res. 2004 Aug 15;64(16):5812-7. doi: 10.1158/0008-5472.CAN-04-0440. Cancer Res. 2004. PMID: 15313924

6

Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling.

Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE, Tonks NK, Mazar AP, Doñate F. Juarez JC, et al. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7147-52. doi: 10.1073/pnas.0709451105. Epub 2008 May 14. Proc Natl Acad Sci U S A. 2008. PMID: 18480265 Free PMC article.

7

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224).

Doñate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, Mazar AP. Doñate F, et al. Among authors: juarez jc. Br J Cancer. 2008 Feb 26;98(4):776-83. doi: 10.1038/sj.bjc.6604226. Epub 2008 Feb 5. Br J Cancer. 2008. PMID: 18253124 Free PMC article.

8

Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.

Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F. Juarez JC, et al. Cancer Res. 2002 Sep 15;62(18):5344-50. Cancer Res. 2002. PMID: 12235005

9

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP. Xu X, et al. PLoS One. 2014 Jan 21;9(1):e85349. doi: 10.1371/journal.pone.0085349. eCollection 2014. PLoS One. 2014. PMID: 24465541 Free PMC article.

10

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY. Lelais G, et al. J Med Chem. 2016 Jul 28;59(14):6671-89. doi: 10.1021/acs.jmedchem.5b01985. Epub 2016 Jul 19. J Med Chem. 2016. PMID: 27433829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters